We performed cytogenetic analysis on fresh bone marrow cells and on progenitor cell colonies in a patient who relapsed after allogeneic BMT for CML and was subsequently treated with donor lymphocyte infusions (DLI). Two Philadelphia-positive clones were identified at relapse. One clone displayed an additional chromosomal abnormality most likely induced by radio-chemotherapy and therefore arising in a single cell. This cell displays the characteristics of a stem cell, since it was able to support 20% of Ph-positive hemopoiesis for 5 months. If the progeny of a single Ph-positive stem cell account for 20% of hemopoiesis, a very low number of leukemic stem cells may sustain relapse after allogeneic BMT. This is in keeping with two observations: (1) at relapse, long-term culture initiating cells (LTC-IC) were all donor-derived and Ph-negative; (2) on average, the pace of the disease is very slow after relapse following allogeneic-BMT. Therefore, we hypothesize that a small number of leukemic stem cells may be involved in the initial events of relapse following BMT for CML. Keywords: CML; donor lymphocyte infusion (DLI); relapse; hemopoietic stem cells; clone A female (UPN 803) of 31 years of age was diagnosed with Ph-positive CML on 9 May 1994. Peripheral blood counts were as follows: Hb = 9.5 g/dl, WBC = 22 10 9 /l, platelets 144 10 9 /l; 0% blast cells; the Sokal score was low (0.5). The transplant course was uneventful and engraftment was documented on day +19 (PMN Ͼ0.5 × 10 9 /l, and platelets Ͼ30 × 10 9 /l). She experienced grade II acute GVHD which was well controlled with CsA and steroids. CsA was continued because of mild chronic GVHD. She became 100% ABO group B Rh-positive on day +120 and 100% 46,XY Ph-negative. This was confirmed every 6 months. The patient had a cytogenetic and hematologic relapse on day +718 post-BMT with partial conversion to recipient ABO blood group (50% 0 Rh-positive): CsA was discontinued and donor lymphocytes (DLI) from the same donor were infused every 21 days as outlined in Table 1 .
She was treated with conventional doses of hydroxyurea. On 23 September 1994 she received an allogeneic BMT from an HLA-DR identical brother while in first chronic phase (1st CP). The donor was ABO group B Rh-positive and the recipient was group 0 Rh-positive. The conditioning regimen consisted of cyclophosphamide 60 mg/kg on day −7, −6 and TBI 333 cGy on day −3, −2, −1 (dose rate = 16-18 cGy/min). GVHD prophylaxis consisted of cyclosporin A (CsA) 2 mg/kg i.v. from day −7 to day −1 and then 1 mg/kg i.v. plus methotrexate 15 mg/m 2 on day +1 and 10 mg/m 2 on day +3, +7, +11. She received a bone marrow cell dose of 4.8 × 10 The transplant course was uneventful and engraftment was documented on day +19 (PMN Ͼ0.5 × 10 9 /l, and platelets Ͼ30 × 10 9 /l). She experienced grade II acute GVHD which was well controlled with CsA and steroids. CsA was continued because of mild chronic GVHD. She became 100% ABO group B Rh-positive on day +120 and 100% 46,XY Ph-negative. This was confirmed every 6 months. The patient had a cytogenetic and hematologic relapse on day +718 post-BMT with partial conversion to recipient ABO blood group (50% 0 Rh-positive): CsA was discontinued and donor lymphocytes (DLI) from the same donor were infused every 21 days as outlined in Table 1 .
Cytogenetic studies at relapse
Cytogenetic analyses were performed on unfractionated bone marrow cells (BM), on CFC and on LTC-IC. Table 1 outlines the differences in Ph-positivity among BM cells, CFC and LTC-IC at the time of relapse and thereafter. At the time of relapse (day +718 after BMT) bone marrow karyotype showed 10% 46XY (donor) and 90% Ph positive (recipient). Two Ph-positive clones were present: 80% 46,XX, t(9;22) (q34;q11); 10% 46,XX, t(3;11) (p21;p15), t(9;22) (q34;q11), del(13) (q14q34). At the time of the first DLI infusion, donor cells (46XY) were 5% in the BM; CFC were 80% 46,XY and all LTC-IC were 46,XY Ph-negative. On day +832 the marrow was 100% Ph-positive, CFC 100% Ph-positive, and LTC-IC could not be grown. Cultures and cytogenetics on cultures were performed as described. Fifty days later (5 months from the first DLI) (day +883) all CFC and LTC-IC were found to be Ph-negative, together with 70% of unfractionated BM cells. On day +963 from BMT bone marrow metaphases were 100% 46,XY Ph-negative and the ABO group was 100% donor (B positive) and remain so 18 months later.
Discussion
Donor lymphocyte infusion (DLI) has become the treatment of choice for patients who relapse after allogeneic BMT for CML, and cytogenetic responses have been reported in a large number of patients. [3] [4] [5] To explain why this DLI is so effective in CML a number of factors have been suggested including the phase of the disease 6 and dose of DLI. 7 In addition, a correlation between percentage of donor lymphocytes prior to DLI 8 or the frequency of progenitor cell-inhibitory lymphocyte precursors 9 with response has been reported.
In the present case we were able to perform sequential cytogenetic analyses which can be summarized as follows: (1) at the time of relapse early progenitors (ie LTC-IC) were all donor derived (100% 46XY); (2) in the early phase after relapse most CFC (80%) and all LTC-IC were Ph-negative; (3) LTC-IC became undetectable in a short period of time (from 40/10 6 to 0/10 6 in 2 months) while the leukemic cell clone became functionally predominant; (4) relapse was sustained by two Ph-positive clones 80% 46,XX, t(9;22) (q34;q11); and 10% 46,XX,t (3;11)(p21;p15), t(9;22)(q34;q11),del (13) (q14q34); 5) cytogenetic remission was delayed (5 months post-DLI) but then occurred very rapidly, with CFC converting from 100% Ph-positive to 100% Ph-negative in 50 days.
The relapse of CML after allogeneic BMT may mimic the early phases of CML, when the Ph-positive clone emerges within normal stem cells. 10 The presence of Phnegative LTC-IC and the low frequency (undetectable) of Ph-positive LTC-IC at the time of relapse is in keeping with previous findings in CML patients in chronic phase. [10] [11] [12] Ph-negative LTC-IC became quickly undetectable with the expansion of the leukemic clone confirming its suppressing effect on normal progenitors. 10 However, at least in this setting, the suppression seems reversible since Phnegative progenitors were again detectable 5 months later, when Ph-positive CFC could no longer be grown.
Perhaps the most intriguing part of this case lies in the presence of a Ph-positive sub-clone characterized by additional chromosomal abnormalities, which were not detected before BMT. There is general consensus that CML arises in a single pluripotent stem cell. It is likely that this cell undergoes a number of self-renewal divisions. However, there are no data available to estimate how many leukemic stem cells are generated from the original one in which t(9;22) translocation has occurred. Indirect evidence that leukemic stem cell numbers may not substantially increase while the disease is in CP derives from the observation that the interval diagnosis-allogeneic BMT does not substantially influence the relapse incidence. 13 No substantial increase in Ph-positive LTC-IC from early to late chronic phase has been documented. 10 In our report two types of chromosomal abnormalites were present at relapse. The [46,XX, t(9;22) (q34;q11); 46,XX, t(3;11)(p21;p15), t(9;22)(q34;q11),del(13)(q14q34)] clones show two fundamental characteristics: (1) the additional alteration [46,XX,t(3;11)(p21;p15),t(9;22) (q34;q11),del(13)(q14q34)] is very likely to have been induced by radiotherapy (TBI) in one single cell; (2) this clone has been self-sustaining for at least 5 months and therefore the cell giving rise to the progeny display the characteristic of a stem cell. It is also very important to point out that the proportion of cells arising from this clone has remained constant for 5 months both in the mature and in the committed compartment. This indicates that one clone did not have any advantage (or disadvantage) over the other. In this particular case, it is possible that one single stem cell may have sustained one-fifth of Ph-positive hematopoiesis for 5 months. In several CML patients Phpositive LTC-IC frequency seems below 1 in 2 to 5 × 10 6 BM mononuclear cells. 10 Considering the mononuclear cell population of a CML patient of around 10 12 cells, this would correspond to a total of 2 to 5 × 10 5 Ph-positive LTC-IC. A low Ph-positive stem cell frequency is therefore not surprising in patients in whom the leukemic burden had been further reduced (3-5 logs) following TBI. Therefore, we would like to formulate the hypothesis that a limited number of leukemic stem cells may be responsible for relapse after allogeneic BMT in patients with CML at least in its early phase. Should this be the case, it may also facilitate a high response rate to DLI 3, 4, 6, 7 and explain the slow pace of the disease after relapse following BMT. 14, 15 Nonetheless, this hypothesis is not in contrast and does not rule out other possible explanations for the efficacy of DLI in CML.
